

**Innovative and rapid detection methods for SARS-CoV-2 infections: recent developments worldwide**

**Abstract**

There are no effective treatments for COVID-19 caused by SARS-CoV-2 viruses worldwide and the effects of vaccines on new genetic variants of the virus are still uncertain. Therefore, initial diagnosis and management are essential for controlling the pandemic. The conventional diagnosis methods for SARS-CoV-2 include molecular tests, serology tests, and computed tomography (CT). However, a few innovative, rapid, and promising detection methods were developed in the last year and this year in different countries of the world. We have discussed the advantages and challenges of these new diagnostic methods besides discussing the widely adopted conventional approaches mentioned above.

We have summarized the most recent and conventional diagnosis methods, including commercially available devices and kits according to their SARS-CoV-2 detection accuracy rates and completion times. We have also discussed the ongoing research in this field. Finally, we have identified some thrust areas of research that could help to identify the new variants of SARS-CoV-2 rapidly and accurately.

Although several diagnostic methods are available, we need more efficient diagnostic tools for SARS-CoV-2 with respect to cost efficiency, accuracy, rapid detection, and user-friendliness, especially for new variants in remote areas of the world.

## **Keywords**

COVID-19; SARS-CoV-2; RT-PCR; CT scan; Rapid detection method; Serology

### **1. Introduction**

On March 11, 2020, COVID-19 was announced as a worldwide pandemic by The World Health Organization. The World is still suffering from its hardship. In 2021, it spread out as a second wave with some mutated strains in different countries. The situation is worse now, especially in India, U.S.A., and Brazil. As per the report published by WHO on the date of July 19, the total number of authenticated cases of COVID-19 is 561,156,416. whereas the number of deaths is 6,365,510 worldwide. According to the same WHO report, a total of 12,166,921,655 vaccine doses have been administered [1]. There are many SARS-CoV-2 variants like alpha, beta, gamma, delta, which are highly transmissible. Now the dangerous and most transmissible delta variant is spreading throughout the World. It already spread out to nearly 100 countries, and in India, a mutated version of the delta variant of SARS-CoV-2, which is delta plus, is probably the most transmissible one [2]. As there is no specific drug for this disease and the vaccines available have limited accuracy on emerging strains, early diagnosis and management are vital to control the pandemic. And an essential feature is that it can be transmitted without the awareness of the host about the infection. Epidemiologic proof has indicated that pre-symptomatic and asymptomatic communication of the virus can drive the current epidemic. Identifying variants in a particular country and tracing their origin has become a top priority in the battle to control the COVID-19 pandemic. There are two primary approaches of SARS-CoV-2 detection - direct analysis of the virus by the spotting of

nucleic acids or spotting via amplification of nucleic acids, and another one is serological or immunological tests to analysis the effects of infection by the virus in the host. Many molecular trial and immunoassays were quickly developed, though numerous are still waiting for regulatory approvals. Clinical validation and formal authorization are still waiting for some. It is reported that many symptomatic patients are negative after the PCR test, and the virus was identified after the computed tomography (CT scan) report. Therefore, a CT scan was also recommended as the third required approach for confirming SARS-CoV-2 diagnosis. The minimum sensitivity of the RT-PCR test is 95% [3], which means up to 5% false-negative results are expected. In the past few months, the COVID-19 virus has had a significant impact on clinical microbiology laboratories. Among the patient samples, sensitive and particular viral nucleic acid detection is crucial for clinical diagnostics, genotyping, and biotechnological advancements. However, there are many methods which are not up to the mark in the criteria of the sensitivity or the specificity to detect nucleic acids at low concentrations and are too costly, time-consuming, and complex to use outside of standard laboratory settings. In the case of the COVID-19 pandemic, RT-PCR can be used to diagnose the presence of SARS-CoV-2 RNA, but inadequate access to reagents and equipment has become a stumbling block. So, we need a more specific, accurate, user-friendly, rapid, and inexpensive SARS-CoV-2 test. We, therefore, have evaluated the performance of several diagnostics technology and their potential use in recent COVID-19 diagnosis, considering the affordability and faster turnaround of results. Besides, we also thought about future tests, which are not only applicable for the SARS-CoV-2 virus but also for the detection of other secondary pathogens. We have discussed some promising tests, such as CRISPR Cas-based testing, aptamer-based testing, next-generation sequencing, etc., and other methods which are still in trial.

## **2.1 Reverse transcription-loop-mediated isothermal amplification (RT-LAMP)**

A new diagnostic method called RT-LAMP, which is a one-step nucleic acid amplification method to multiply particular sequences of RNA of SARS-CoV-2 was evolved by a German research team and it is appropriate for other RNA viruses as well. Amplification at a constant temperature, exclusion of a thermal cycler, a faster test result, and potentially a larger diagnostic capacity is some of the fundamental advantages possessed by this method. The RT-PCR test needs different temperatures in one cycle. The temperature of the solution has to be interchanged from 92°C to 56°C and again to 72°C in each two minutes. So, this test needs an expensive thermal cycle [4-5]. This process is equivalent to conventional PCR tests, with the deviation that nucleic acid amplification that take place at one temperature (65°C only). So, an expensive thermal cycle is not needed. The main advantages of this method are as follows: a. the assay is so fast that results can be obtained within 30 minutes, b. positive samples are amplified as early as within 10 minutes and c. it works in a wide pH rang [6-7]. The cost of LAMP diagnostic method is reasonable and does not need a complex. and expensive piece of equipment. The assays can be done with less skills and minimum infrastructure. It is an accurate, confirmatory, cost-effective, rapid and user-friendly molecular diagnostic method which are the basic address to address a pandemic like the COVID-19. For RT-PCR, isolation of RNA and specification of viral RNA are critical initial steps. The following steps involve the conversion of RNA to DNA and then a semi-quantitative reaction occurs using oligonucleotides specific for viral cDNA [8-12]. Most of the reagents in these processes are highly temperature-sensitive. In the case of RT-LAMP, this is a simplified version of the RT-PCR method. This method does not require an initial RNA isolation step [13-14]. So, another plus point of RT-LAMP is that the reagents can be stored at 4°C (ordinary household refrigerator). In contrast, the reagents for RT-PCR require storage and transport at -20°C, which escalates the cost.

There is an acute need for a user-friendly technique for COVID-19 testing in remote areas specially for highly populated countries like India. The RT-LAMP technique has been recently adopted in India with new trade names. Although the LAMP technique is familiar in Western countries for the past five years or more, the procedure is totally unique to the Indian in vitro diagnostic (IVD) market. The LAMP technology has been indigenously developed by Agappe Diagnostics in India and ICMR (Indian Council of Medical Research) has approved and validated their kit which is named LUME ScreennCov [15]. The target genes of this system for SARS-CoV-2 are N gene and RdRp gene and turnaround time is 10 to 35 minutes after RNA extraction with 98.7% sensitivity.

The negative aspect of the LAMP is specificity to COVID-19 only. It can inform whether a person is infected or not with SARS-CoV-2 or other RNA viruses but cannot give information on other diseases or symptoms that have been secondarily developed after COVID-19. This test is unable to inform clinicians if a patient has been previously infected with the virus or if a patient has developed any immunity against the virus.

## **2.2 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) based testing**

Recently the development of CRISPR-based methods has reshaped molecular diagnosis. It applies the cutting-edge CRISPR-Cas9 technology and Drs. Emmanuelle Charpentier and Jennifer A. Doudna bagged the Nobel Prize in Chemistry in 2020 for this. CRISPR-Cas9 is used by geneticists and medical researchers to manipulate parts of the genome by removing, adding, or altering sections of the DNA sequence. The advantages of the CRISPR system include specificity, speed, precision, solidity, proficiency, and adaptability, which have motivated researchers to eveloped CRISPR-based diagnostic and therapeutic methods [17,18]. There are many types of new diagnostic methods designed based on CRISPR Cas technology, e.g., CRISPR Cas 12, CRISPR Cas 9, CRISPR Cas 19 etc.

Recently in the U.S.A. COVID-19 infections detected among patients using CRISPR-Cas 12 based assay from extracted patient sample RNA which is known as SARS-CoV-2 DNA Endonuclease-Targeted CRISPR Trans reporter (DETECTR) [18-20]. The reporting time of DETECTR method is faster than PCR methods, and this was an excellent alternative diagnostic tool. Another CRISPER-based method is RNA-guided Cas13, which can identify the genomic characteristics of SARS-CoV-2 and provides an important detection strategy for SARS-CoV-2 [21-22] was developed by scientists from Broad Institute of U.S. This method is named as SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) test, which uses Cas12 for detection of SARS-CoV-2. SHERLOCK was first developed in 2017 and has been improved since then, and is currently being used in COVID-19 detections [24,25]. Both DETECTR and SHERLOCK utilize the promiscuous cleavage and degradation of neighbouring ssRNA and ssDNA by Cas 12a and Cas13, respectively, to cleave and activate a reporter. The signal from this reporter is easily detectable and can be quantified further to determine the presence and quantity of DNA, RNA or a mutation of interest in viral genome. Together these two methods demonstrated the excellent power of CRISPR-based diagnostic approach.

A unique diagnostic testing kit for COVID-19 was developed by Tata Medical and Diagnostics Ltd. (Tata MD) in India and disclose as TATA MD CHECK, industrially. Tata MD CHECK is FNCAS9 Editor-Limited uniform Detection Assay (FELUDA) method which is a CRISPR Cas 9 based innovation that was introduced in India by the CSIR-Institute of Genomics and Integrative Biology (IGIB) for verifying COVID [26-28]. They have designed a guide RNA (a short synthetic RNA composed of a scaffold sequence necessary for Cas binding and a user-defined nucleotide spacer that defines the genomic target to be modified) complementary to target the SARS-CoV-2 genome sequence. The Tata CRISPR test is the world's first CRISPR Cas-9 based diagnostics method. In 'FELUDA', it works like a

pregnancy detection strip and it changes colour if the virus is detected, and it is very user friendly [29-30]. Feluda is the World's first COVID-19 detection test kit that uses Cas9. It was tested on 2000 patients and reported 96% sensitivity and 98% specificity and the results also supported by RT-PCR (comment of Harsh Vardhan, Union Health Minister of India) [31].

### **2.3 The Hyris System<sup>TM</sup> COVID-19 diagnostic kit developed in Italy**

The Hyris System<sup>TM</sup> is a detection tool for SARS-CoV-2, it works based on nucleic acid in nasopharyngeal swabs or nasal swabs specimens was a miniature of real-time PCR for the in vitro detection. This diagnostic kit is unique because it is very user-friendly and offers rapid diagnosis in any common environmental setting, at any time. This kit also utilizes the Artificial Intelligence, that provides real time access to results, already automatically interpreted, on its cloud-based software platform. Hyris Ltd. is a multinational Italian company that developed this diagnostic kit as a point-of-care rapid test “bKIT virus Finder COVID-19” [32-34]. The Hyris System<sup>TM</sup> identifies COVID-19 in samples collected from contaminated surfaces, which represent a potential threat for both patients and healthcare workers. The entire diagnosis time takes about an hour, which is another advantage. The procedures are simple as follows. The nasopharyngeal swabs are inserted into the nasal cavity and placed in vials, then 15 ml of reaction is added to the swab in the vial. These reagents present in the kit are designed to reduce the impact of the RNase contained in the clinical specimen which promote nucleic acid extraction before the retro transcriptase step. Detection can be made through “positive” or “negative” results assigned by the samples. It is designed as fluently and quickly to use in emergency conditions and remote areas. Hyris System<sup>TM</sup> provides more or less same results as RT-PCR method. It is a complete portable suite, which is versatile, fast, and reliable<sup>35, 36</sup>. The main advantage of this test is it is fully automatic. In Canada, Hyris kit was recently approved as a point-of-care test. for human diagnostics. So,

this test is very important for quick and prompt detection, and it can be used during travelling.

There has some negative aspect too, when a patient with a viral load which is very close to the limit of detection of the method shows “false negative” results. In some cases, it gives “inconclusive” results.

#### **2.4 A new low-cost COVID-19 diagnostic test developed in India, by IIT Kharagpur: COVIRAP**

A new corona virus diagnostic machine and test kit were recently developed by the researchers at the Indian Institute of Technology (IIT), Kharagpur, India, was approved by the Indian Council of Medical Research (ICMR). The machine costs below \$100 and one test costs approximately \$8 to \$10 only. During the testing conducted using 200 patient samples, the machine displayed over 93% sensitivity and almost 98% specificity. This highly promising and cheap diagnostic method showed an accuracy level slightly lower than RT-PCR method at a fraction of the cost. A Group of Companies, India and Bramerton Holdings LLC, USA has been licensed for commercialization for this kit. The manufacturing cost is very low compared to a RT-PCR machine [37,38]. A generic step-wise isothermal nucleic acid-based testing technology used for the quick diagnosis of the pathogen. After getting the nasal swab or saliva samples the results could be available within 45 minutes only. Once the sample was processed in the machine after being mixed with solutions, treated paper strips-similar to pregnancy strips-are dipped into it, and the emergence of coloured lines will depict the presence of the virus, according to Kharagpur IIT team [39]. It is self-sufficient, does not depend on separate RNA extraction, is very affordable pre-programmable portable device. A free smart phone’s app has also been developed to provide a simple interpretation of results to patients. A more advanced version of COVIRAP has also been developed using a step-

wise isothermal nucleic acid testing technology for the rapid diagnosis of pathogenic infections including COVID-19 [40]. The COVIRAP platform is capable to diagnose other diseases detections where pathogens are detectable by nucleic acid-based tests. This is not only for one-time diagnostic test for COVID-19 but it will distinctive for global infectious disease diagnosis in the future. As stated above, COVIRAP requires a small portable equipment, and ideal for use in rural areas and in less developed countries where air-conditioned laboratories are unavailable. The portable unit is very easy to operate with a minimum training in all kind of environments [41,42]. Despite all these advantages, the negative aspect of COVIRAP is slightly lower sensitivity and specificity than RT-PCR [43].

## **2.5 Aptamer-based Testing**

An aptamer is a single-stranded artificial nucleic acid that is used to detect pathogens. DNA aptamers has capability to bind with single-stranded DNA molecules to a particular target with high affinity and specificity. The aptamers were considered for COVID-19 diagnosis because of easy modification options and their high stability [44]. The aptamer-based strategy was recently considered as an up-and-coming method for the detection of the COVID-19. This method is a economical, accurate, and low time-consuming test. Similar to antibodies, aptamers bind specifically to their targets. Aptamer targets include a variety of small molecules such as amino acids, nucleotides, and antibodies [45], but can also be larger, including proteins [46], viruses, and bacteria [47]. Aptamers can concede viral proteins and have been introduce in the rapid detection of viruses and also as antiviral agents in treating infection. The aptamer-based sensor works based on binding two aptamer probes to the same protein target that brings the ligation DNA region into close proximity, thereby initiating ligation-dependent qPCR amplification. By using a simple, equivalent and fast detection workflow with 120 minutes this system discovers serum nucleocapsid protein [48].

During the outbreak of SARS-CoV in 2003, scientists have reported that the nucleocapsid (N) protein of SARS-CoV-2 is an excellent diagnostic biomarker [49]. In the primary stage of corona virus infection (day 1-10), the viral N protein is much more delicate for detection (90% positive) compared to viral nucleic acid (42.9%) or antibodies (21.4%) in patient's sera [50]. Thus, aptamer-based methods should be very effective for virus detection in the pioneer stages of SARS-CoV-2 infections. A research team from India, the Vellore Institute of Technology (VIT), has recently developed an aptamer-based point-of-care (POC) diagnostic kit for the quick diagnosis of COVID-19. Another research team from India, the translational Health Science and Technology Institute (THSTI) in Faridabad, has evolved an aptamer-linked immobilized sorbent assay (ALISA) for detecting SARS-Co-V2 [51,52]. For this test, the aptamer attaches to the full-length spike protein of the virus, which plays a vital role in binding to the receptors found on human cells, and gains entry into the cell. The ALISA assay has 90% sensitivity and 99% specificity, according to the research team. The main advantage of this method is that it works on mutated strains also and has very little chance of false positive or negative result [53-58]. Some weakness of this testing method includes the release of aptamers through the renal system due to its low molecular weight. Another limitation is that the toxicity of aptamers on the human body is unknown at this time [59].

## **2.6 Next-Generation Sequencing (NGS)**

Next-generation sequencing (NGS) is an enormous aligned sequencing technology, which can offer ultra-high throughput, expandability, and speed. This method can allow clinicians to test many genes of an infectious microorganism simultaneously. The NGS provides an effective way to identify the new coronavirus strains and their mutations, it accustomed to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. The NGS method can be effective with transmission tracing, rapid viral diagnosis, verifying the accuracy of other diagnostic tests, and checking antiviral vaccine effectiveness. By the

use of next-generation sequencing it can generate information about the genomic sequence of the virus which are present in a sample. The sequence data can be used not only for diagnosis but also for research purposes. The NGS method allows DNAs to be read directly, nucleotide by nucleotide, and thus very effective for the diagnosis of mutated strains with altered genomes. So, in the long run, the NGS can help researchers and clinicians for adopting the proper identification and look into treatment options [60-62].

The uses of NGS methods are of various types; among them, the shotgun method and the target enrichment method are fundamental to diagnose SARS CoV-2. A next-generation shotgun metagenomics method was developed by Illumina, which has the ability to detect not only coronavirus but also other pathogens which are present in the sample [63]. So, it will help patients get information about their disease very quickly in one test. Also, the NGS can be used to monitor the presence of harmful bacteria and viruses in environmental samples collected from surfaces and air. It provides high coverage uniformity, low duplication rates, strand specificity with a streamline [64,65]. Understanding genomic mutations across different samples by the NGS can help understand the epidemiology of disease transmission [66]. With time, the NGS method is becoming cheaper, more accessible, faster, and more reliable. It is now becoming one of the gold-standard methods for clinical diagnosis [67].

### **2.7 Computed Tomography (CT) Scanning for early detection of SARS-CoV-2**

In recent days, CT-Scan has been a very useful method that may be used for early COVID detection. Chest CT is a very important tool for pneumonia diagnosis, so it rapidly diagnoses COVID-related pneumonia also. The chest imagination related to COVID-19 was first published in January 2020 and included bilateral lung involvement and ground-glass opacities in the majority of hospitalized patients [68]. Chest CT is important to detect both alternative diagnoses and complications of COVID-19-related acute respiratory distress

syndrome, pulmonary embolism and heart failure, while its role for prognostication requires investigation. In an experiment, out of 240 patients, 60% had positive RT-PCR results, and 89% had positive chest CT scans. So, its sensitivity is higher than RT-PCR test [69]. It should be used for those patients who may have classic symptoms of the illness but have a negative RT-PCR test result. CT scanning provides us with a powerful non-invasive mean for the diagnosis and monitoring for COVID-19 [70-72]. This method is also applicable for situations when a CT pulmonary angiogram might be required to rule out pulmonary embolism in a patient who is on anticoagulants and steroids and is not showing any signs of recovery. This is also useful in cases where the patient is in intensive care units (ICUs). The usage of CT-Scan also diagnoses the dangerous COVID-19 associated fungal super-infectious like Aspergillosis or mucormycotic [73-75]. A consensus about the role of chest imaging (mainly CT scanning) in managing patients during the COVID-19 pandemic recently, the Fleischner society has published and discussed different clinical scenarios, including the seriousness of respiratory disease, pre-test probability, risk factors for disease progression, and critical resource limitation [76]. High-risk hospitalized patients with comorbidities, which may need advanced health care support, urgently need chest CT scans. For the investigation of post-COVID infection complications and patients' pulmonary position, it is very important. The meta-analysis study showed that chest CT scans might be beneficial in the early detection of cases of COVID-19. According to the experimental reports, sensitivity and specificity values for CT scans were respectively 86.7% and 93.6%, in a recent meta-analysis including 63 studies [77].

The negative aspect of this test is that it does not properly distinguish between COVID-19 and other respiratory infections, like bacterial pneumonia and seasonal flu. Another problem is that some patients with COVID-19 may have normal chest CT reports.

The table below shows the sensitivity and completion times of different new and classic diagnostic methods for COVID-19, adopted worldwide.

*Table I. Technologies based on accuracy levels:*

Technology	Sensitivity
RT-LAMP	97.5%
CRISPR Cas13 based SHERLOCK	97%
CRISPR Cas9based FELUDA	96%
Hyris Kit	95%
COVIRAP	94%
Aptamer based	90%
Next-generation sequencing	Not reported
CT scan	86.7%

*Table II. Technologies based on the completion times:*

Technology	Time requirement
RT-LAMP	30 minutes
FELUDA (CRISPR Cas9 based)	45minute
CRISPR Cas13 based SHERLOCK	60minute
CT Scan	60minute
COVIRAP	60minute
Hyris Kit	120minute
Aptamer based	120minute
Next generation sequencing	720minute

### **3. Other recent developments**

Finally, we will briefly discuss the most recent developments in the COVID-19 diagnostics in the last several months. Recently a novel sensor system was evolved that can detect SARS-CoV-2 from saliva samples in one second, which is much faster than the existing methods. In the Journal of Vacuum Science & Technology B published this new rapid and sensitive test [78], it uses a technique that amplifies the binding signal for a target biomarker in a sophisticated way. The biosensor strip looks similar to glucose test strips with a small microfluidic channel at the tip to apply test fluids. A few electrodes are exposed to the fluid, Within the microfluidic channel which are coated with gold, and COVID-relevant antibodies are already attached to the gold electrode surfaces. The sensor strips are connected to a circuit board via a connector. A low-level electrical current flow between the gold electrode coated with COVID-19 antibody and the electrode. This signal is then returned to the circuit board for analysis. The strips can be discarded after use, but the circuit board is reusable. This recently developed technology is highly cost-effective and portable.

FLU SC2 Multiplex Assay, a different types of PCR test which can detect any of three respiratory viruses simultaneously: the COVID-19 virus, influenza A and influenza B (flu). Only a single test helps to determine three viruses, was recently developed [79]. The assay provides a sensitive, nucleic acid-based diagnostic tool for the evaluation of specimens from patients in the acute phase of infection. On July 2, 2020 the US Food and Drug Administration (FDA) granted Emergency use Authorization (EUA) for this test [80]. Symptoms shared between the two infections, Influenza and COVID-19, include chills, fever, difficulty breathing, cough, fatigue, body aches, diarrhoea and vomiting. COVID-19 spreads more rapidly and is often more severe. Only multiple assay testing can differentiate the two. This new Multiplex PCR contains multiple primer sets in a single PCR mix and produces amplicons which are of different sizes and sequences [81]. Although expensive and labour-

intensive, this new method can quickly pinpoint agents responsible for acute respiratory infections.

A new bioluminescence testing method was recently developed in the Netherlands. It is a point-of-care antibody-based testing method that detects specific viral proteins. The existence of antibodies in the blood reflects that person was infected with the corona virus and had a past immune response. The sensor in this method works based on bioluminescence. If a certain protein or antibody is present in the sample, specific luciferase enzymes will emit light. When the device contains no biomarker of interest, one type of luciferase enzyme emits green light, but when a sample containing target biomarkers, a second luciferase enzyme that holds the key to detection will work [82]. Another research team in Japan has developed a rapid, cost-effective platform for quantitative antibody detection that also uses bioluminescent proteins, cotton threads, and a smartphone [83]. This detection method takes roughly 30 minutes time for complete. The sensitivity of this method ranged from 84.0% to 97.6%.

Another lab-on-chip testing technique is a new method that was recently developed in Singapore, where all required RT-PCR reagents are stored on a microchip. The whole process can be programmed to add them to a micro reaction chamber alongside a patient's biological sample with SARS-CoV-2 viruses to fulfill each PCR step. This technology is known as VereCoV [84]. This test is used in conjunction with VerePLEX bio system, and the test results can be used as supplementary data for diagnosis. A negative result does not preclude SARS-COV-2 infection and should not be used as a sole basis for treatment or other patient management decisions when this method is being used. Testing with VereCoV One Mix Detection kit is intended for use by trained laboratory professionals who are proficient in using the VerePLEX biosystem, which is another limitation [85].

A different types rapid detection method evolved that merges the PCR test steps and allows direct testing of the crude patient sample. Instead of RNA purification, in this method added inhibitor-resistant enzymes, which target the specific compounds that obstruct RNA amplification, such as mucin (a main component of mucus in the respiratory tract). So, this method reduces the inversion time from sample collection and also removing the need for the RNA purifying chemicals. This method is speedy, cost friendly and the availability of enzymes and reagents are obtainable, have high resistance to mucin-like inhibitor compounds that generally inhibit PCR reactions, rendering the regular PCR tests inaccurate sometimes. The biochemical mix of crude sample and inhibitor-resistant enzymes and reagents are transfer in a single tube, then it inserted into a laboratory thermocycler, a machine that is used to amplify genetic materials [86]. This upgraded PCR testing method capitulate results in just 36 minutes which is a quarter of the time of existing gold-standard RT-PCR tests. Not only COVID testing, this method can also be used to measure other viruses and bacteria, including the dengue virus.

#### **4. Conclusions**

Despite recent decreasing trends of COVID-19 in some countries, it appears that we are into the third phase of the pandemic, and COVID-19 will continue to be a long withstanding health hazard for the foreseeable future. Mass testing for SARS-CoV-2 needs millions of tests per country per week- the opinion of most epidemiologist, this mass testing method is the only way to control the current crisis. But governments of different countries are struggling to arrange adequate testing facilities. One reason is that the 'gold standard' test to detect SARS-CoV-2 – based on a confluence lab technique called the reverse-transcription polymerase chain reaction, or RT-PCR- requires trained employees and specific chemical supplies. This test report will be available within six hours from the time of sample collection. This testing method requires expensive instruments that take hours to provide results and this test will

available only in labs that have standard and centralized services. For these problems, control the number of tests that can be done, especially in developing countries. According to 10<sup>th</sup> august,2021 report of India, over 40% districts still not have a single RT-PCR lab for covid testing. The wealthy regions of the World, like the United States, providers have reported a serious scarcity of test kits and required materials, such as nose swabs to chemical reagents - because of supply chain problems. This review has summarized all these issues. We have discussed some newly emerging diagnostic methods which could be more specific, accurate, and cost-effective than RT-PCR. Because some of these methods are less expensive so they can be and should be used in developing and underdeveloped countries, especially with a high population. CRISPR-based FELUDA, SHERLOCK, Hyris kit, and COVIRAP are low time consuming, user friendly, and very appropriate for low-resource countries. The completion time durations for testing could be critical in emergencies and could help save a life. Chest CT scan is also an important tool for detecting Covid related respiratory syndrome, which is already very popular in recent clinical practices. CT-Scan is also an efficient detection tool for post covid complications. RT-LAMP is a contemporary technology with 97.5% sensitivity and 99.7% specificity and better than current RT-PCR, and it can be used in every country, including both low and high economies. An aptamer-based method is a highly promising technology being used for SARS-CoV-2 detections, but this method is still under developmental processes. Next-generation sequencing is an advanced technology with reasonable accuracy, and it can be used in developed countries with lower populations in moderate budgets. Despite all these recent developments, we believe there is still an urgent need to develop more practical, precise, and accurate detection test methods for SARS-CoV-2 and other emerging pathogens for protecting the global population.

**COMPETING INTERESTS DISCLAIMER:**

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper.

## References

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19. 11 March 2020.
2. Vintetz. J. What are the different types of corona virus? Medical News Today. 2020 September 27.
3. Kortela E, Kirjavainen V, Ahava M J, Jokiranta S T., But J, Lindahl A, et al. Real-life clinical sensitivity of SARS-CoV2 RT-PCR test in symptomatic patients. Plos One.2020; 21:16(5):e0251661.
4. Ryding S. What is RT-LAMP Technology? New Medical Life Science. 2021;
5. Jonathan.L, Burgk S, Schmithausen R, Li D, Ben-Shmuel B, Israeli O, et al. LAMP Seq: Population-scale COVID-19 diagnostics using a compressed barcode space. BioRxiv.2020; 025635
6. Thompson D, Lei Y. Mini review; recent progress in RT-LAMP enable COVID-19 detection. SD.2020; Volume 2, Issue 1:100017.
7. Mohammadi A, Esmailzadeh E, Li Y, Bosach RJ, Li Z; et al. SARS-CoV-2 detection in different respiratory sites: A system review and meta-analysis. E Bio Medicine 2020; 59:10290.

8. Aoki MN, de Oliveria Coelho B, Goes LGB, Minoprio P, Durigon EL, Morello LG, et al. Colorimetric RT-Lamp SARS-CoV-2 diagnostic sensitivity relies on color interpretation and viral load. *SR*.2021; 11, 9026.
9. Erceer T, Salit M. Testing at scale during the COVID-19 pandemic. *NRG*2021; 22:415-426.
10. Ganguli A, Mostafa A, Berger J, Aydin M, Sun F, Valera E, et al. Rapid isothermal amplification and portable detection system for SARS-CoV-2. *PNAS* 2020; 117(37): 22727-22735
11. Inaba M, Higashimoto Y, Toyama Y, Horiguchi T, Hibino M, Iwata M, et al. Diagnostic accuracy of LAMP Versus PCR over the course of SARS-CoV-2 infection. *IJID*.2021; Volume 107:195-200.
12. de Oliveria KG, Estrela PFN, Mendes GM, Dos Santos CA, Silveira-Lacerda EP, Durate GRM, et al. Rapid molecular diagnostics of COVID-19 by RT-LAMP in a centrifugal polystyrene-toner based micro device with end-point visual detection. *R. So Chem*.2021; 146:1178-1187
13. Mautner L, Baillie CK, Herold HM, Volkwein W, Guertler P, Eberle U, et al. Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP). *Virology* 2020;17(1):160.
14. Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, et al. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med* 2020; vol.12 Issue 556: eabc7075.
15. Vasudevan D.M. Corona virus RT-LAMP: A new technology for the detection COVID-19. *The Hindu*.2020 28<sup>th</sup> November; Sci-Tech.

16. Rahimi H, salehiabar M, Barsbay M, Ghaffarlou M, Kavetsky T, Sharafi A, et al. CRISPR systems for COVID-19 Diagnosis. ACS Sens.acssensors.2021; 6, 4:1430-1445.
17. Ding R, Long J, Yuan M, Yang H, Chen M, Chen S, et al. CRISPR/Cas system: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. Front. Cell. Infect Microbiol.2020; 23:639108.
18. Abbott T.R., Dhamdhare G., Liu Y., Lin X, Goudy L, Zeng L, et al.Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and Influenza. Cell 2020; 18:865-876.e12.
19. Dara M, Talebzadeh M. CRISPR/Cas as a potential Diagnosis technique for COVID 19. Avicenna J Med Diotechnol.2020; 12(3):201-202
20. Stration J. CRISPR Vs COVID-19 how gene editing help beat a virus? Biotechniques.2020; Vol.69 (5):327-329.
21. J P. Broughton, Deng X, CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol.2020; .38(7):870-874.
22. Berber B, Aydin C, Kocabas F, Guney-Esken G, Yilancioglu K, Karadag-Alpaslan M, et al. Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics. Gene Ther.2021; 28:290-305.
23. Gadwal A, Roy D, Khokhar M, Modi A, Sharma P, Purohit P. CRISPR Cas-New Molecular Scissors in Diagnostics and Therapeutic of COVID 19. Indian J clin Biochem. 2020;1-9.
24. Detection of SARS-COV\_2 with SHERLOCK One-Pot Testing. The New England Journal of Medicine.2020 8<sup>th</sup> October.

25. Lall S. SHERLOCK\_based one step test provides rapid and sensitive Covid-19 selection. MIT News .2020 5<sup>th</sup> may.2020.
26. Kumar P, Malik YS, Ganesh B, Rahangdale S, Saurabh S, Natesan S, et al. CRISPR-Cas system: An approach with potentials for COVID-19 diagnosis and Therapeutics. Front cell Infect Microbiol, 2020; 10:576875
27. Feluda Test-A new rapid test method for the identification of SARS-CoV-2. Milenia biotec .2020 10<sup>th</sup> May.
28. Rajalakshmi Explained: How does India's feluda COVID-19 test work? Science Wire. 2020 28<sup>th</sup> October.
29. DuttA.Covid-19: Feluda test kit tweaked to detect mutated variants quickly. India News.2021 15<sup>th</sup> March.
30. India's Feluda Covid-19 test cheaper, faster alternative to RT-PCR.HealthWorld.com. 2020 29<sup>th</sup> September.
31. PachaA. Explained: FELUDA Paper strip test for coronavirus. The Hindu.2020 12<sup>th</sup> October.2020.
32. Hyris Brings Its Corona Virus Environmental Testing kit to U.S. Globe Newswire. 2020 May21.
33. Pissarello M. Heirs COVID-19 Environmental Testing or how to think to a phase 2. Linkedin .2020 April 8.
34. Erensoy S. COVID-19 Pandemisinde SARS-CoV-2 Mikrobiyolojik Tani Dinamikler (SARS-CoV-2 and Microbiological diagnostic Dynamics in COVID-19 pandemic). Mikrobiyol Bul.2020; 54(3):497-509.

35. D'Cruz RJ, Currier AW, Sampson VB. Laboratory Testing Methods for Novel severe Acute Respiratory Syndrome-Coronavirus-2(SARS-CoV-2). *Front Cell Dev Biol.*2020;8:468.
36. Miscio L, Olivieri A, Labonia F, Feo GD, Chiodini P, Poretella G, et al. Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection. *J of Transl Med.*2020;18:488
37. Coronavirus IIT kharagpur launches COVIRAP diagnostic technology. *The Hindu.*2021 21<sup>th</sup> April;
38. Ghosh S. Global Launch of COVIRAP-Nucleic acid-based Point-of-Care Diagnostic Device for COVID-19 and beyond. *The KGP Chronicle.*2021 21<sup>th</sup> April.
39. COVIRAP: A quick Covid-19 Test. *Drishti.*2020 22<sup>th</sup> October.
40. Mascarenhas A. Quick Covid-19 test from IIT Kharagpur: How it works, why it matters. *The Indian Express .*2020 22<sup>th</sup> October;
41. IIT Kgp Commercialises COVID-19 diagnostic device COVIRAP. *Biospectrum.*2021 21<sup>th</sup> April;
42. IIT Kharagpur's 'Covirap' diagnostic machine gets ICMR certification. *Healthworld.com.*2020 21<sup>th</sup> October.2020.
43. Agrawal S. IIT Khagarpur unveils COVIRAP, a Covid test that costs Rs 500 & delivers results in 1 hour. *The Print.*2020 21<sup>th</sup> October;
44. Verma N, Patel D, Pandya A. Emerging diagnostic tools for detection of COVID-19 and perspective, *Biomed. Microdevices* 2020; 22, 83.
45. Ellington A. D, Szostak J.W. selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. *Nature.*1992; 355,850-852.

46. Schneider D, Tuerk C, Gold L. selection of high affinity RNA ligands to the bacteriophage R17 coat protein. *J Mol. Biol.* 1992; 228,862-869.
47. Torres-Chavolla E, Alcilja E.C. Aptasensors for detection of microbial and viral pathogens. *Biosensors Bioelectr.* 2009; 24, 3175-3182.
48. Liu R, He L, Hu Y, et al. A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers. *Chem Sci* 2020; issue44:12157-12164.
49. Che XY, Hao W, Wang Y, Di B, Yin K, Xu Y-C, et al. Nucleocapsid protein as early diagnostic marker for SARS. *Emerg Infect Dis.* 2004;109110:1947-9.
50. Li YH, Li J, Liu XE, Wang L, Zhou YH, Zhuang H. Detection of the nucleocapsid protein of severe acute respiratory syndrome coronavirus in serum: comparison with results of other viral markers. *J virol Methods.* 2005;130(1):45-50.
51. Chen Z, Wu Q, Chen J, Ni X, Dai J. A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein. *Virol Sin* 2020; 35(3):351-354
52. Kumar V, Yadav GS, Banerjee BD. Aptamer Based Diagnosis: A cost- Effective and suitable point of care testing Method against SARS Coronavirus-2(SARS-Cov-2) and other Rapidly Spreading Diseases. *Curr. Biotechnol.* 2021; Volume10, issue1.
53. Yang G, Li Z, Mohammed I, Zhao L, Wei W, Xiao H, et al. Identification of SARS-CoV-2 Against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. *Signal Transduct Target Ther.* 2021;6(1):227

54. Ravi N, Cortade D. L, Ng E, Wang SX. Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. *Biosens. Bioelectron.* 2020; 165:112454.
55. Prasad R. Aptamer-based assay developed for corona virus detection. *The Hindu.* 2020 13<sup>th</sup> July. Sci-Tech.
56. Pinpoint's Low-Cost Handheld Covid-19 Aptamer-based Diagnostic device in Development. *Rapid Microbiology.* 2020 9<sup>th</sup> March;
57. Aptamer Group and mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test. *News Medical Life Science.* 2020 March 18;
58. Godkin D. Shape-changing aptamers detect SARS-CoV-2 with immediate results. 2020 Dec. 30. *Bio World.*
59. Torabi R, Ranjbar R, Halaji M, Heiat M. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review. *Mol Cell Probes.* 2020; 53:101636.
60. Chen X, Kang Y, Luo J, Pang K, Xu X, Wu J, et al. Next-generation sequencing Reveals the progression of COVID-19. *Front Cell Infect Microbiol.* 2021; 11:632490.
61. Chiara M, D'Erchia AM, Gissi C, Manzari C, Parisi A, Resta N, et al. Next generation sequencing of SARS-Cov-2 genomics: Challenges, applications and opportunities. *Brief Bioinform.* 2021; 22(2):606-630.
62. Lemieux J. Moving beyond PCR: Next-generation sequencing enters the COVID-19 testing arena. *Clinical OMICs.* 2020; Vol.7:No.4
63. Carter LJ, Garner LV, Smooth JW, Li Y, Zhou Q, Saveson CJ, et al. Assay Techniques and Test development for COVID-19 Diagnosis. *ACS Cent Sci.* 2020; 6(5):591-605.

64. Carey J. Next generation sequencing of community-based COVID-19 samples to detect emerging variants. . UIC today.2021 June28;
65. Harnessing next generation sequencing to detect SARS-CoV-2. Institute of Molecular Biotechnology of the Australian Academy of Science. 2021 May25.
66. How next generation sequencing can help identify and track SARS-CoV-2. Nature portfolio.
67. Muthuirulan P.NGS: offering a glimmer of hope in the fight against COVID-19. Drug Target Review .2020 11<sup>th</sup> September;
68. Thomas C. Kwee, Robert M. Kwee. Chest CT in COVID-19: what the Radiologist Needs to know. Radio graphics.2020; Vol.40: No-7.
69. Bollineni VR, Nieboer KH, Dorinh S, Buls N, de Mey J.The role of CT imaging for management of COVID-19 in epidemic area: early experience from a University Hospital. Insights imaging.2021; 12(1):10.
70. Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis.2020;34:101627.
71. Mahmoud H, Taha MS, Askoura A, Aleem M, Omran A, Aboeela S. Can chest CT improve sensitivity of COVID-19 diagnosis in comparison to PCR? A meta-analysis study. EgyptJ Otolaryngol.2020; 36(1):49.
- 72.Tang Z, Zhao W, Xie X, Zhong Z, Shen D. Severity assessment of COVID-19 using CT image features and laboratory indices. Phys Med Biol.2021; 66(3):035015
73. Tenda ED, Yulianti M, Asaf MM, Yunus RE, Septiyanti W, Wulani V et al. The Importance of chest CT scan in COVID-19. Acta Med Indones.2020; 52(1):68-73.

74. Pakdemirli E, Mandalia U, Monib S. Positive Chest CT Features in Patients With COVID-19 Pneumonia and Negative Real-Time Polymerase Chain Reaction Test..Cureus.2020; 12(8):e9942
75. Harmon S.A, Sanford T.H, Xu S, Turkbey EB, Roth H, Xu Z, et al. Artificial intelligence for the detection of COVID-19 Pneumonia on chest CT using multinational databases. Nat Commun. 2020; 11, Article No: 4080
76. Mahadavi A, MD, Haseli S, MD, Mahadavi A, MD, Bakhshayeshkaram M, MD, Foroumandi M, MD, Nekooghadam SM, MD, et al.The Role of Repeat Chest CT Scan in the COVID-19 Pandemic. Acad Radiol.2020;27(7): 1049-1050.
77. Bahrami-Motlagh H, MD, Taheri MS, MD, Abbasi S, MD, Haghighi-Morad M, MD, Salevatipour B, MD, Darazam IA, MD. Accuracy of Low-Dose Chest CT scan in Detection of COVID-19. Radiology.2020; Vol.2:No.3
78. COVID-19 Testing Method Gives Results Within One Second. Journal of Vacuum Science & Technology B; 2021 May 18.
79. New COVID-19 Testing Method Gives Result in 1 second, Say Scientists: Report by NDTV; Press Trust of India, 2021 May 20.
80. Test for Flu & COVID-19. Canters for disease control and prevention. Updated 2021 July13.
81. Covid-19 and the flu: can we multiplex our way out of this? Integrated DNA Technologies. 2021, Jan19.
82. Bioluminescence lights up traces of covid-19 in the blood. Eindhoven university of Technology. 2021, 29<sup>th</sup> July.

- 83.** Kim M. Detecting antibodies with Bioluminescence. Optics & Photonics.2020 25<sup>th</sup> June.
- 84.** Littlejohns P. Five innovative methods designed to improve Covid-19 testing. NS  
MEDICAL DEVICES.2020 29 September.
- 85.** Koh D. Veredus Laboratories' vereCoV detection Kit obtains provisional approval for  
IVD use. Mobi health news; 2020 March 03.
- 86.** Improved Testing Method Produces COVID-19 Results in 36 minutes. Technology  
Networks; 2020 July 28.